Clinical data | |
---|---|
Trade names | Actonel, Atelvia, Benet, others |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Bisphosphonate[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 0.63% |
Protein binding | ~24% |
Metabolism | None |
Elimination half-life | 1.5 h |
Excretion | Kidney and fecal |
Identifiers | |
| |
Chemical and physical data | |
Formula | C7H11NO7P2 |
Molar mass | 283.112 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Risedronic acid, often used as its salt risedronate sodium, is a bisphosphonate used to treat and prevent osteoporosis or to treat Paget's disease of bone.[1] It is taken by mouth.[1]
Common side effects include constipation, nausea, headache, and rash.[1] Other side effects may include esophageal inflammation, esophageal perforation, osteonecrosis of the jaw, low calcium, and muscle pain.[1] Use is not recommended in those with significant kidney problems.[2] It works by inhibiting the cells which break down bone.[1]
Risedronic acid was patented in 1984 and approved for medical use in 1998.[3] It is available as a generic medication.[4] In the United States it costs about 30 USD per month as of 2021.[4] In the United Kingdom it costs the NHS about £10 per month.[2]
References edit
- ^ a b c d e f g "Risedronate Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 19 July 2021.
- ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 770. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 9783527607495. Archived from the original on 2021-03-18. Retrieved 2020-08-27.
- ^ a b "Risedronate Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 19 July 2021.